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A B S T R A C T   
Pharmaceutical compounds ingested by humans are metabolized and excreted in urine and feces. These me-
tabolites can be quantified in wastewater networks using wastewater-based epidemiology (WBE) methods. 
Standard WBE methods focus on samples collected at wastewater treatment plants (WWTPs). However, these 
methods do not capture more labile classes of metabolites such as glucuronide conjugates, products of the major 
phase II metabolic pathway for drug elimination. By shifting sample collection more upstream, these unam-
biguous markers of human exposure are captured before hydrolysis in the wastewater network. In this paper, we 
present an HPLC-MS/MS method that quantifies 8 glucuronide conjugates in addition to 31 parent and other 
metabolites of prescription and synthetic opioids, overdose treatment drugs, illicit drugs, and population 
markers. Calibration curves for all analytes are linear (r2 > 0.98), except THC (r2 = 0.97), and in the targeted 
range (0.1–1,000 ng mL− 1) with lower limits of quantification (S/N = 9) ranging from 0.098 to 48.75 ng mL− 1. 
This method is fast with an injection-to-injection time of 7.5 min. We demonstrate the application of the method 
to five wastewater samples collected from a manhole in a city in eastern Massachusetts. Collected wastewater 
samples were filtered and extracted via solid-phase extraction (SPE). The SPE cartridges are eluted and 
concentrated in the laboratory via nitrogen-drying. The method and case study presented here demonstrate the 
potential and application of expanding WBE to monitoring labile metabolites in upstream wastewater networks.   
1. Introduction 
The opioid epidemic is widespread in the US, causing nearly 450,000 
overdose deaths since 1999 [1]. Each wave of the epidemic ushers in 
more fatal and non-fatal overdoses. Estimates of the intensity of each 
wave are based on first responder reports and hospital records. Unfor-
tunately, compiling these types of data can take a matter of years. 
Moreover, individuals who experience non-fatal opioid overdoses may 
never actively seek medical care [2,3]. These hidden populations 
suffering from opioid use disorder may benefit from empirically proven 
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interventions surrounding harm reduction and behavioral health. 
However, detection of these individuals continues to be challenging. 
Some tactics like syndromic surveillance using social media or devel-
opment of prescription drug monitoring programs have been imple-
mented by public health authorities to better understand the spread of 
the opioid epidemic, but these measures lack ground truth clinical 
sampling to confirm described trends. Therefore, a clear need exists for 
healthcare-independent, de-identified, noninvasive approaches for 
measuring opioid exposure. 
One such approach is wastewater-based epidemiology (WBE), a 
technique of analyzing residential wastewater for human-excreted drug 
metabolites to estimate population-level exposures to pharmaceuticals 
and other drugs of abuse [4–9]. WBE permits noninvasive monitoring of 
large populations through existing public infrastructure. Thus, it enables 
population health assessments that are independent of disease indicators 
provided by healthcare facilities or based on expensive in-person survey 
protocols. WBE samples can be obtained as needed and wastewater 
analyte dynamics can be used to guide public health interventions and 
harm reduction policy development [10–11]. Several methods exist for 
quantifying licit and illicit drugs in wastewater utilizing a combination 
of solid-phase extraction and mass spectrometry, typically liquid chro-
matography coupled to triple quadrupole mass spectrometry [12–19]. 
Unfortunately, methods developed for this purpose often include only a 
subset of opioid metabolites or only those in their unchanged forms 
[8,20–24]. In the human body, opiates are primarily metabolized via 
phase II glucuronidation [25]. These glucuronide conjugates, unlike the 
unchanged parent forms, act as direct indicators of human exposure. 
Wastewater epidemiologists have recently called for the inclusion of 
glucuronide conjugates in back-calculations of human exposure [26]. 
Unfortunately, once introduced to the sewer system, the travel time of 
metabolites from the point of injection to the WWTP can be up to 24 h 
[27]. With some exceptions such as codeine-6-glucuronide, glucur-
onidated metabolites, once introduced to the wastewater system, un-
dergo rapid degradation via enzymatic hydrolysis and may be absent or 
at such low concentrations that they evade the detection limit of ana-
lyzers at the WWTP level [24,28–31]. 
One approach to address this shortcoming is to move WBE sampling 
upstream in the sewer networks, thereby capturing glucuronide conju-
gates and other potentially time-sensitive metabolites prior to chemical, 
biological and physical transformations that occur in the sewer. Previ-
ous studies have sampled upstream to achieve more granular data of the 
contributing population such as in prisons or on college campuses 
[32–35]. This advance unlocks the potential for higher resolution 
community-level surveillance for opioid exposure and importantly ex-
pands the classes of target molecules to include direct metabolites of 
human exposure [36]. 
This study develops and validates a high performance liquid chro-
matography - tandem mass spectrometry method tailored to a panel of 
opioids including eight glucuronide conjugates: acetaminophen glucu-
ronide, codeine-6-glucuronide, hydromorphone-3-glucuronide, 
morphine-3-glucuronide, norbuprenorphine glucuronide, naloxone-3- 
glucuronide, oxymorphone-3-glucuronide and (±)-11-nor-9-carboxy- 
delta9-THC glucuronide. We select three multiple reaction monitoring 
(MRM) transitions per target analyte to increase specificity between 
opioids which have similar structures and fragmentation patterns as 
opposed to existing methods which commonly utilize two per analyte. 
Finally, we pilot this technique in an upstream manhole catchment 
thereby demonstrating the feasibility of this analytical technique at 
critical access points in wastewater networks. To our knowledge, this is 
the first observation of naloxone-3-glucuronide in an upstream manhole 
catchment. 
2. Materials 
ACT, ACT-Glu, AMP, BEG, BUP, CCN, CDN, CDN-Glu, CFN, 
THCCOOH, EDDP, HCD, HCT, HMP, HMP-Glu, THCOH, MAM, MAMP, 
MDA, MDMA, MPH, MPH-Glu, NBP-Glu, NCD, NHCD, NLX, NLX-Glu, 
NMPH, NOCD, NTRM, NTX, OCD, OMP, OMP-Glu, OTRM, PAG, THC, 
THCCOOH-Glu and TRM reference standards and their deuterated an-
alogues used for internal standards (ACT-D4, AMP-D8, BEG-D8, BUP- 
D4, CCN-D3, CDN-D6, CDN-Glu-D3, CFN-13C3, THCCOOH-D3, EDDP- 
D3, HCD-D3, HCT-D3, HMP-D3, THCOH-D3, MAM-D6, MAMP-D8, 
MDA-D5, MDMA-D5, MPH-D6, MPH-Glu-D3, NBP-Glu-D3, NCD-D3, 
NHCD-D3, NLX-D5, NLX-Glu-D5, NOCD-D3, NTRM-D3, NTX-D3, OCD- 
D6, OMP-D3, OMP-Glu-D3, OTRM-D6, PAG-D5, THC-D3, THCCOOH- 
Glu-D3 AND TRM-D3) were purchased from Cerilliant Corporation 
(Round Rock, TX, USA) at concentrations of either 1 mg mL− 1, 2 mg 
mL− 1 or 100 µg mL− 1. ACT-Glu (5 mg, 99.9% grade purity) was pur-
chased from Sigma Aldrich (St. Louis, MO, USA). LC/MS Optima Grade 
acetonitrile, methanol, water and formic acid used for mobile phases 
and elution solvents were obtained from ThermoFisher Scientific (Aga-
wam, MA, USA). Ultra-high purity (UHP) Nitrogen gas for sample con-
centration and UHP Argon for the LC/MS collision gas were sourced 
from Airgas (Billerica, MA, USA). UHP Nitrogen for the LC/MS nebu-
lizing gas was supplied by a nitrogen generator (Peak Scientific, Bill-
erica, MA). Liquid chromatographic separation was performed on a 
Horizon Vanquish UHPLC system equipped with an autosampler 
compartment, a temperature-controlled column compartment, and a 
binary pump system coupled to a TSQ Altis triple stage quadrupole MS/ 
MS system equipped with a heated electrospray ionization (H-ESI) 
source (ThermoFisher Scientific, San Jose, CA, USA). Analytical sepa-
rations were performed using a reversed-phase AccucoreTM Biphenyl 
column (100 × 2.1 mm I.D., 2.6 μm). The column was set up in-line with 
a column pre-heater, pre-filter, and a DefenderGuard column (10 × 2.1 
mm, AccucoreTM Biphenyl packing). TraceFinder 4.1 General Quanti-
tation Software was used for data acquisition. The TSQ Altis Tune 
application software was used to select the MRM transitions and to 
optimize the MS ionization settings. 
3. Method development 
A summary of the target analytes in the method with their respective 
drug classifications and parent compounds can be found in Table S1. The 
precursor and fragment ions for each target analyte and internal stan-
dard were determined by preparing individual 1,000 ng mL− 1 solutions 
in 50:50 v/v methanol:water and directly infusing them to the mass 
spectrometer. Using a glass syringe and a syringe pump, the solutions 
were infused at a rate of 30 µL min− 1 and teed into the LC flow until good 
spray stability was observed (<15% RSD). The CID gas was set to 1.5 
mmTorr. Three MRMs for each target analyte and 2 MRMs for each in-
ternal standard were recorded along with their optimized collision en-
ergies, polarities and RF lens voltages (Table S2). A mixture of all 
reference materials was prepared at 10,000 ng mL− 1 and infused to the 
H-ESI source, in-line with the LC flow at 50% B to optimize the ioniza-
tion settings (Table S3). The optimized LC mobile phase solutions were 
0.1% formic acid in water (A) and 0.1% formic acid in methanol (B) at a 
flow rate of 0.5 mL min-1. We compared both methanol and acetonitrile 
as the ‘B’ mobile phase and observed methanol to yield better retention 
and separation. The developed gradient elution program was: 3.50 min 
equilibration at 0% B, hold 0% B for 0.2 min, increase to 99% B over 2.3 
min, hold constant for 1 min, decrease to 0% B and hold for 0.5 min. The 
autosampler compartment was set to 4 ◦C. The column oven was 
maintained at 40 ◦C in the ‘Still Air’ thermostatting mode. The injection 
volume was set to 1 μL, and the autosampler needle was rinsed before 
and after each injection for 15 s with a solution of 40:20:20 acetonitrile: 
isopropyl alcohol:acetone. 
We investigated two chromatographic columns for this work: the 
Accucore™ Biphenyl and the Accucore™ Polar Premium reversed-phase 
columns from Thermo Fisher Scientific. We found the Accucore™ 
Biphenyl to retain and separate these target analytes better than the 
Accucore Polar Premium column. 
During method development, we ran an experiment to determine the 
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minimum elution volume required to elute our compounds from the 15 g 
SPE cartridge. Milli-Q samples were spiked in triplicate with a mixture of 
target analytes for a concentration of 200 ng mL− 1 in the final extract. A 
blank sample was also prepared. The cartridges (n = 4) were washed 
with 40 mL of a solution of 5% methanol in water v/v and eluted with 
120 mL of 100% methanol with the wash and elution fractions collected 
at 20 mL intervals. Each fraction was spiked with a solution of internal 
standards for a final extract concentration of 50 ng mL− 1. The eluents 
were then dried, reconstructed in 1 mL of HPLC grade water and 
analyzed by the HPLC-MS/MS method. 
Additionally, we performed a spiking recovery experiment to 
confirm the feasibility of the solid-phase extraction protocol in this 
matrix. For this experiment, we scaled down the loading volume and 
SPE cartridge resin to replicate field sampling while also preserving 
expensive reference standards. In the laboratory, we prepared triplicate 
samples (V = 140 mL) of Milli-Q water (spiked), wastewater (spiked) 
and grab wastewater (blank). The Milli-Q and wastewater samples were 
spiked with a mixture of target analytes at 5 ng L-1. All solutions were 
loaded at a rate of 1 mL min− 1 onto 6 cc, 500 mg Waters HLB SPE 
cartridges using a vacuum manifold. The cartridges were washed with 4 
mL of 5% methanol in water v/v and eluted with 20 mL of 100% 
methanol. The eluents were spiked with a mixture of internal standards 
for a final extract concentration of 50 ng mL− 1, dried with UHP nitrogen, 
reconstructed in 1 mL of HPLC grade water and analyzed by the HPLC- 
MS/MS method described previously. The recovery in wastewater was 
corrected by the background concentration in the wastewater blank. 
4. Method validation and quality control 
The developed method was validated for specificity, linearity (r2), 
accuracy, carryover, precision, range, instrumental quantification limit 
(IQL) and detection limit (IDL) in accordance with the FDA’s Analytical 
Procedures and Methods Validation for Drugs and Biologics Guidance for 
Industry [37]. We prepared a series of dilutions from a 5,000 ng mL− 1 
working mixture of all target analytes into nine calibrators in a solution 
of 1% methanol in Milli-Q water: 0.1, 0.5, 1.0, 4.9, 10.0, 48.8, 97.5, 
487.5, and 975 ng mL− 1. Each calibrator was spiked with the appro-
priate amount of internal standard (IS) mixture for a final amount of 50 
ng mL− 1. Calibrators>20% different from the theoretical concentration 
were excluded from the calibration curve and a minimum of seven 
calibrators were required to validate a calibration curve. The calibration 
curves for all analytes were set to ignore the origin and had 1/X 
weighting. Area ratios of the target analytes to its respective internal 
standard were used to create the calibration curves. The IDL for each 
target analyte was determined by selecting the lowest concentration 
which had a signal-to-noise ratio (S/N) equal to 3, good chromato-
graphic peak shape (6–10 MS scans per peak), the presence of at least 
one confirming ion, and fragment ion ratios within 20% of the expected 
fragmentation pattern pulled from the calibrators. The IQL for each 
target was determined by selecting the lowest concentration which 
satisfied the IDL requirements with both confirming ions present and S/ 
N = 9 (see Table 1). An r2 > 0.98 was considered suitable for linearity. 
The specificity of the method was ensured by using the internal standard 
mode of calibration. Any effects of the wastewater matrix such as 
retention time drift, chemical interferences, or ion suppression or 
enhancement are corrected by the internal standard. Carryover for all 
analytes was evaluated by injecting the highest calibrator in the series 
followed by an injection of milli-Q water solvent blank spiked with the 
appropriate amount of the internal standard working mixture and 
calculating the percent carryover between the injections. 
The precision of the method was determined by repeatedly injecting 
a sample with 5 ng mL− 1 of a solution of target analytes (n = 8) and 
calculating the relative standard deviation (%RSD). A %RSD < 15% was 
considered acceptable for validation. To ensure the quality of the 
method, we prepared a pooled sample consisting of 10 µL combined 
from each sample in the batch. The pooled sample was analyzed every 
five injections to check for instrument drift. A continuous calibration 
verification (CCV) sample equivalent to the fifth calibrator concentra-
tion is also injected periodically. Concentrations in the CCV<20% 
different than the theoretical amount are considered acceptable. A sol-
vent blank spiked with internal standards is injected periodically to 
account for carryover. 
5. Application to wastewater samples 
We applied the developed method on wastewater samples (n = 5) 
collected from a manhole in a city in eastern Massachusetts. We used a 
custom-designed sampling device consisting of peristaltic pumps, a 
Durapore 0.22 µm filter, a custom-packed 15 g Oasis HLB solid-phase 
extraction (SPE) cartridge and a silicone rubber pickup tube equipped 
with a pond filter to prevent large debris from clogging the tubing 
(described further in Endo et al 2020). The sampling device was set to 
pump wastewater for 30 s every five minutes for 24 h. The effluent from 
the SPE cartridge was collected and the loading volume was measured 
for each sample. Upon completion of sample collection, the SPE car-
tridges were removed from the device and returned to the laboratory on 
ice. The samples were kept at − 20 ◦C until analysis and analyzed within 
72 h. Gonzalez-Marino et al. investigated the storage stability of similar 
analytes on HLB resin SPE cartridges and found minimal losses [38]. 
The SPE cartridges were washed with 40 mL of a 5% v/v solution of 
methanol in water then eluted with 120 mL of 100% methanol at a rate 
of 1 mL min− 1. We observed that a minimum of 120 mL of 100% 
Table 1 
Summary of method validation parameters: instrumental detection limit (IDL), 
instrumental quantitation limit (IQL), linearity and precision.  
Compound IDL (S/N = 3), pg 
injected 




ACT 9.8 9.8 9.9 
ACT-Glu 4.9 4.9 9.1 
AMP 4.9 4.9 20.1 
BEG 0.5 0.5 36.9 
BUP 0.5 0.5 6.5 
CCN 1.0 0.1 3.6 
CDN 1.0 4.9 13.8 
CDN-Glu 0.5 1.0 11.9 
CFN 1.0 4.9 6.2 
EDDP 0.1 0.1 2.7 
HCD 1.0 4.9 11.4 
HCT 0.1 0.1 18.7 
HMP 1.0 4.9 11.4 
HMP-Glu 0.1 1.0 23.5 
MAM 1.0 4.9 6.3 
MAMP 0.1 0.5 2.9 
MDA 0.5 0.5 2.8 
MDMA 0.1 4.9 40.0 
MPH 1.0 4.9 9.0 
MPH-Glu 0.1 4.9 9.3 
NBP-Glu 4.9 9.8 4.3 
NCD 1.0 4.9 11.4 
NHCD 4.9 4.9 6.0 
NLX 0.5 1.0 8.3 
NLX-Glu 0.5 1.0 8.1 
NMPH 1.0 4.9 21.6 
NOCD 0.5 1.0 10.2 
NTRM 0.5 1.0 3.1 
NTX 0.5 4.9 6.9 
OCD 0.5 1.0 8.4 
OMP 1.0 1.0 7.5 
OMP-Glu 0.1 0.5 6.7 
OTRM 0.1 1.0 9.4 
PAG 0.5 4.9 34.5 
THC 9.8 48.8 18.5 
THCCOOH 1.0 4.9 8.6 
THCCOOH- 
Glu 
4.9 48.8 15.3 
THCOH 1.0 4.9 2.8 
TRM 0.1 4.9 3.4  
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methanol was required to elute some cannabinoids (THCCOOH and 
THC) which determined the elution volume used (Figure S1). The 
methanol fractions were collected in 4 × 40 mL glass vials and spiked 
with 50 ng of the internal standard mixture. The eluents were placed 
under a gentle stream of UHP nitrogen until the samples were at near 
dryness. Samples were reconstructed in 1 mL of 1% v/v methanol in 
water solution. 
The wastewater concentration (Cw) for each analyte was calculated 
by summing the concentrations of all four vials, multiplying by the 
reconstruction volume (Vr), and dividing by the total SPE cartridge 
loading volume (Vl) (1). The vial concentrations described here are all 
blank-corrected. 
Cw =
[(C1 + C2 + C3 + C4)xVr]
Vl
(1)  
6. Results and discussion 
6.1. Method development and validation results 
The developed HPLC-MS/MS method is fast with an injection-to- 
injection time of 7.5 min. The chromatographic column can retain and 
separate the opioid compounds despite their similar chemical structures. 
This instrumental method is suitable for high-throughput applications, 
especially in labs interested in monitoring opioid usage in the commu-
nity. To maximize the efficiency of the instrument turnaround time, the 
sample preparation steps need to be further optimized to shorten the 
overall processing time. 
The method is sensitive for all analytes with IDLs lower than 1 ng 
mL− 1 except for ACT-Glu, AMP, NBP-Glu, NHCD, and THCCOOH-Glu 
which have IDLs below 5 ng mL− 1. ACT and THC have a slightly 
higher IDL of 10 ng mL− 1. Similarly, the instrumental limit of quanti-
fication (IQL) was as low as 0.1 ng mL− 1 for some analytes. THC and 
THCCOOH-Glu have slightly higher IQL of 50 ng mL− 1. The upper limit 
of the calibration curve is 1,000 ng mL− 1. If the observed concentration 
in an unknown sample falls above the upper limit, the sample is diluted 
to an appropriate level, spiked again with internal standards and re- 
analyzed by the instrument. 
The calibration curve linear equation parameters and r2 values can 
be found in Table S4. The linearity for all analytes is excellent (r2 > 0.99) 
except for BUP, EDDP, THCOH, and NMPH which have r2 > 0.98. THC 
has a reasonable r2 of 0.97 that fell below the threshold for validation. As 
a result, THC could only be qualitatively detected here. The precision of 
the instrument in measuring each target analyte in wastewater is below 
the threshold of 15% RSD for all compounds except for PAG, THC, BEG, 
AMP, HCT, NMPH, MDMA, HMP-Glu which ranged from 16 to 40% 
RSD. In each of the solvent blank samples, the concentration of all target 
analytes was not detected, so we were unable to calculate the percent 
carryover. 
6.2. Results from case study 
The manhole used here serves an area that is 84% residential with a 
population of approximately 5,300 people. The estimated maximum 
hydraulic retention time from the point of injection to the manhole 
selected is 45 min. The distance from the manhole to the wastewater 
treatment plant is approximately 10 miles. The five samples were 
collected daily from Friday, October 4th to Tuesday, October8th, 2019. 
There were no significant rain events during the sampling period. The 
sample volumes collected on days 1–5 were 1.270, 1.475, 1.510, 1.485, 
and 1.370 L, respectively. 
The analytes with the highest average wastewater concentrations 
over the five-day period were benzoylecgonine, the major urinary 
metabolite of cocaine and the population biomarker class compounds: 
caffeine, acetaminophen, phenylacetylglutamine, and hydroxycotinine 
(Fig. 1, Table 2). Most analytes were detected in all samples, except for 
NBP-Glu, 6-MAM, NLX-Glu and THCCOOH-Glu which were detected in 
four samples and ACT-Glu and NCD which were detected in fewer than 
Fig. 1. Measured concentrations of all analytes in wastewater samples using the developed method.  
Table 2 
Observed wastewater concentrations (ng L− 1) for samples taken over five days 
from a manhole in eastern Massachusetts. n.d.: Not detected.  
Compound Wastewater Concentration (ng L− 1) 
Day 1 Day 2 Day 3 Day 4 Day 5 
ACT 58619.6 70558.4 46603.7 75501.6 43012.6 
ACTG 8.6 13.4 n.d. n.d. n.d. 
APT 258.1 292.5 222.5 181.4 337.6 
BEG 2510.7 1456 3894 3115 1060.6 
BUP 13.3 17.6 33.7 56.1 36 
CCN 267.8 471.3 283.7 226.3 73 
CDN 26 16 16.4 21.3 20.6 
CDNG 104.4 58.4 80.9 40.9 27.9 
CFN 71660.4 74241.8 69271.4 69825.4 76495.9 
CTHC 453.3 435.4 466.5 382.6 469.1 
EDDP 1.1 4.8 0.8 0.9 0.5 
HCD 6 2.6 3.5 4.4 4.3 
HCT 1319.4 1280.1 1107.9 1060.9 1348.9 
HMP 2.5 2.5 1.2 1 2.2 
HMPG 138.2 90.1 185.2 27.7 26.7 
HTHC 149.3 214.4 208.6 539.4 482.5 
MAM 3.2 n.d. 6.5 8.8 4.5 
MAMP 19.2 22.4 17 9.3 12.1 
MDA 9.7 12.6 6.5 7.2 12.6 
MDMA 13.1 5.6 27.2 10.2 4.6 
MPH 95.9 85.1 84.2 68.5 118.8 
MPHG 133 87.9 178.8 26.7 26.6 
NBPG 5.7 4.7 3.2 3.1 n.d. 
NCD 21.8 n.d. n.d. n.d. n.d. 
NHCD 5.4 4.4 5.1 5.5 3.5 
NLX 3.3 5.4 7.9 6.2 6.5 
NLXG 8 7.9 5.7 6.8 n.d. 
NOCD 16.8 20.9 15.8 21.4 86.6 
NTRM 25.6 16.3 19.4 25.2 33.3 
NTX n.d. n.d. n.d. n.d. n.d. 
OCD 8.2 8.9 5.6 2.8 25.3 
OMP 6 4.9 4.5 9.3 12.1 
OMPG 3.6 6.1 4.3 3.5 25.7 
OTRM 43.1 41.5 62.1 65.9 82.4 
PAG 6659.9 5319.9 6501.5 5068.1 5012.3 
THC 29.6 49.5 18 33.4 30.9 
THCG 30.7 35.3 39.2 15.2 n.d. 
TRM 51.4 44.9 77.1 146.9 88.2  
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two samples (Fig. 2). For some of the parent and glucuronide conjugate 
pairs such as THC and THCCOOH-Glu, NLX and NLX-Glu, HMP and 
HMP-Glu, MPH and MPH-Glu, CDN and CDN-Glu, the wastewater con-
centration of the glucuronide conjugate was higher or roughly equal to 
the amount of the parent compound (Fig. 2). This ratio of glucuronide 
conjugate to parent compound may be explained by the glucuronide 
being the primary urinary metabolite for these pairs [25,39–40]. 
Conversely, the average wastewater concentration of acetaminophen is 
four orders of magnitude higher than its glucuronide conjugate, acet-
aminophen glucuronide. This could potentially be explained by larger 
amounts of acetaminophen discarded down the drain. The relatively low 
detection rate of norcodeine may be because it is only a minor urinary 
metabolite of codeine [41]. Naltrexone, a treatment for alcohol and 
opioid abuse, was not detected in any of the samples. This could 
potentially be explained by fewer naltrexone users in our selected 
catchment area. 
We found that THCCOOH is the metabolite reliably used to estimate 
human consumption of cannabis (THC) in a WBE context. Previous 
studies have shown difficulty measuring THC in aqueous wastewater 
without also including sludge due to its high lipophilicity [42] 
Furthermore, THCOH is only an intermediary metabolite which is ulti-
mately excreted in urine as THCCOOH. It is also expected that some 
amount of THCCOOH-Glu transforms back to the carboxylic form in the 
wastewater environment. Although, Bijlsma et al. suggest acidifying the 
samples to pH 2 to reliably quantify THCCOOH in a wastewater matrix, 
adjusting the pH in an in-situ extraction device is challenging in this 
application and further work is needed to achieve pre-acidification. 
In order to collect and observe the more labile analytes of interest in 
this study, we utilized an in-situ wastewater sampling device. Unlike 
most WBE studies which obtain a composite sample from a WWTP 
before bringing it to the laboratory for processing, this device filters and 
loads the wastewater sample to the SPE cartridge instantaneously, 
thereby preserving the glucuronide conjugates and other sensitive 
compounds. However, one significant and notable disadvantage of this 
sampling method is that the internal standards are only introduced to 
the wastewater sample after the cartridge is returned and eluted in the 
lab. Therefore, the extraction efficiency is not considered, making 
further WBE calculations of population consumption challenging. 
While the sample collection procedure described here is outside the 
scope of the HPLC-MS/MS method validation, this sampling strategy is 
valuable for the future of wastewater surveillance at the neighborhood 
level. To demonstrate the effectiveness of the SPE cartridges in the field, 
we performed a spiking recovery experiment in the laboratory to 
investigate the recoveries of the SPE protocol in both Milli-Q and 
wastewater matrices. The recoveries from the experiment are summa-
rized in Table S5. Overall, the opiates had reasonable recoveries in Milli- 
Q water (>30%) with HMP-Glu and MPH-Glu having lower average 
percent recoveries of 22.8 and 27%, respectively. Many compounds had 
better percent recoveries in wastewater even after being wastewater 
blank corrected with average percent recoveries >70% for all com-
pounds selected except for BUP which had a recovery in wastewater of 
17.7%. 
6.3. Implications and future work 
The ability to assay wastewater samples at both upstream and 
Fig. 2. (Top) Comparison of the wastewater concentrations for the glucuronide conjugates and their respective parent compound. (Bottom) The ratio of the 
wastewater concentration for the glucuronide conjugate to its parent. 
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downstream sources for a large panel of both prescription and illicit 
opioids significantly advances the ability of researchers and public of-
ficials to understand exposure to opioids among key populations. 
Importantly, the incorporation of glucuronide conjugates draws the 
distinction between human exposure to opioids compared to opioids 
that may be discarded via the wastewater system. This distinction allows 
public health officials to recognize patterns of opioid use that are a result 
of actual human exposure compared to a composite analysis of both 
human exposure plus potential discarded opioids. 
Numerous pharmacokinetic studies have been performed on the 
human excretion rates of the target analytes in this study which are 
further used in WBE back-calculations of human exposure of the parent 
compounds [44–54]. Adding glucuronide conjugates to these back- 
calculations expands the suite of human-specific markers of consump-
tion, especially for analytes such as naloxone which are primarily 
excreted as the glucuronide conjugate [48]. 
The method described here is subject to some limitations. Regarding 
the sample collection, one major issue is the inability to introduce the 
internal standards to the sample prior to the solid-phase extraction 
loading step. Further experiments and hardware revisions should be 
explored to investigate if introducing the internal standards sooner is 
possible, perhaps during the in-situ sample collection or as a dose to the 
cartridge upon arrival to the lab. Another limitation of this method is the 
large elution volume required to elute each SPE cartridge. This results in 
long drying times and potential handling errors when splitting the 
sample into vial fractions. In future applications, the relatively large 
total elution volume could be collected and dried in a single container 
using a rotary evaporator rather than drying individual fractions with 
nitrogen gas. 
Notably, some of the glucuronide conjugates were not observed on 
all five days of the study. There are many possibilities for why these 
conjugates were absent. One possible explanation could be the different 
usage dynamics of the parent drugs across the days of the week [43]. 
Their absence could also potentially be explained by partial degradation 
prior to sample collection or abnormal dumping of bleach cleaning 
products to the sewage network that day. We know that dilution can 
affect the signal of these compounds in wastewater, however we did not 
observe significant rain events during the sampling period. Another 
explanation could be changes in the bacterial concentrations in the 
wastewater across the different days. Future work is needed to better 
constrain the in-sewer stability of glucuronide conjugates at different 
injection points in the upstream wastewater network. Furthermore, the 
method itself can be expanded and revalidated to include emerging 
opioids or drugs of abuse (i.e. synthetic drugs or fentanyl analogs). This 
technique may enable higher resolution understanding of substance use 
and the impact of treatment programs at the community and neigh-
borhood level. 
7. Conclusions 
We developed a sensitive HPLC-MS/MS method for the quantifica-
tion of 31 opioids, illicit drugs, and population biomarkers as well as 8 
glucuronide conjugates in wastewater. Chromatographic separations 
were performed using an Accucore™ Biphenyl column (100 × 2.1 mm I. 
D., 2.6 μm), with a 7.5-minute runtime between injections. The instru-
mental method was validated for selectivity, linearity, IQL, precision, 
and accuracy. The calibration curves for all analytes are linear (r2 >
0.98) in the targeted range (0.1–1,000 ng mL− 1), except for THC with r2 
= 0.97, and instrumental limits of quantification (S/N = 9) for all 
analytes ranged from 0.1 to 48.8 ng mL− 1. We applied the method to five 
wastewater samples collected from a manhole using an in-situ waste-
water sampling device. Results from a recovery experiment found 
reasonable recoveries utilizing an in-situ sampling device in a manhole. 
These results demonstrate the ability to capture glucuronide conjugates 
indicative of direct human exposure to various licit and illicit opioids as 
well as naloxone, the overdose reversal drug. This allows for high 
resolution detection of changes in population exposure to opioids as well 
as potential overdoses which may be reversed in the field and never 
present for medical care. By understanding the distribution of opioids 
and naloxone usage, public health officials can use these data to better 
allocate opioid abuse services and interventions in their communities 
[10]. Lastly, to more accurately estimate population consumption using 
an upstream sampling method, further investigation of internal standard 
spiking inside of an in-situ robotic sampling device is required. 
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